HC Wainwright Issues Pessimistic Forecast for HRMY Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities researchers at HC Wainwright reduced their Q3 2026 earnings per share estimates for Harmony Biosciences in a note issued to investors on Tuesday, May 12th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.97 per share for the quarter, down from their previous forecast of $1.09. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.34 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q2 2027 earnings at $1.06 EPS, Q3 2027 earnings at $1.25 EPS, Q4 2027 earnings at $1.48 EPS, FY2027 earnings at $4.69 EPS and FY2030 earnings at $7.11 EPS.

HRMY has been the topic of several other reports. Mizuho set a $50.00 price objective on Harmony Biosciences in a research report on Thursday, February 19th. Weiss Ratings downgraded Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. UBS Group reduced their price objective on Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Needham & Company LLC reduced their price objective on Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Finally, Bank of America reduced their price objective on Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating on the stock in a research report on Wednesday, February 25th. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $40.89.

Harmony Biosciences Stock Down 2.8%

Shares of NASDAQ:HRMY opened at $30.49 on Friday. The company has a quick ratio of 3.56, a current ratio of 3.58 and a debt-to-equity ratio of 0.15. Harmony Biosciences has a 52-week low of $25.52 and a 52-week high of $40.87. The stock’s fifty day simple moving average is $29.40 and its 200-day simple moving average is $33.18. The company has a market capitalization of $1.77 billion, a P/E ratio of 12.29, a P/E/G ratio of 0.21 and a beta of 0.97.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.21). Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The company had revenue of $215.39 million during the quarter, compared to analysts’ expectations of $220.84 million. During the same quarter in the prior year, the company earned $0.78 earnings per share. The firm’s revenue was up 16.6% compared to the same quarter last year.

Hedge Funds Weigh In On Harmony Biosciences

Several institutional investors have recently added to or reduced their stakes in HRMY. EverSource Wealth Advisors LLC increased its stake in Harmony Biosciences by 589.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after purchasing an additional 643 shares during the last quarter. Allworth Financial LP increased its stake in Harmony Biosciences by 286.7% during the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock worth $30,000 after acquiring an additional 602 shares during the last quarter. Leonteq Securities AG acquired a new stake in Harmony Biosciences during the fourth quarter worth about $30,000. National Bank of Canada FI acquired a new stake in Harmony Biosciences during the third quarter worth about $40,000. Finally, Clearstead Advisors LLC increased its stake in Harmony Biosciences by 145.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock worth $44,000 after acquiring an additional 699 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors and hedge funds.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.